

Special Issue

Virus-Like Particle & Nanoparticle Vaccines against Viral Infections

Message from the Guest Editor

The scope of this Special Issue is to bring together the latest scientific and technical developments made in the field of antiviral virus-like particle and nanoparticle vaccines. I sincerely hope this exchange would contribute to the conception of novel nano-vaccines with desirable properties. Keywords:

- Virus-like particles
- Synthetic nanoparticles
- Nanoparticulate systems
- Administration routes for nanoparticle vaccines
- Functionalization of nanoparticles with antigens and adjuvants
- Therapeutic antiviral nano-vaccines
- Prophylactic antiviral nano-vaccines
- Modulation of the immune response

Guest Editor

Dr. Vladimir Temchura

Institute of Clinical and Molecular Virology of the Universitätsklinikum Erlangen, Schlossgarten 4, 91054 Erlangen, Germany

Deadline for manuscript submissions

closed (1 February 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/41954

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).